Motilal Oswal's research report on Dabur
Dabur’s 3QFY24 performance was largely in line. Consolidated revenue increased 7% YoY (in line) with the India business witnessing a growth of c.9% YoY and the International segment at 1% YoY (12% in cc). India volume growth stood at 6% YoY (organic growth at 4%). HPC business was up 7% YoY with Oral care, Hair Oil, Home Care, and Shampoo clocking 8%, 5%, 7%, and 11%, respectively. The Healthcare division was weak at 3% growth, due to the delayed winter season. Both Chyawanprash and honey gained market share. F&B clocked 5% organic growth with the Badshah portfolio up by 33% YoY. GM was up 300bp YoY and 30bp QoQ to 48.6%. High A&P spend (up 36% YoY) limited the EBITDA margin expansion to 30bp YoY to 20.5%. EBITDA was up 8% YoY.
Outlook
The operating margin also has scope for improvement in the medium term, hovering in the c.20% band over the last eight to nine years (unlike peers that enjoyed expansion). We value Dabur on 48x Dec’25 EPS to arrive our TP of INR 635. We reiterate our BUY rating on the stock.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.